Phase 2b dose-ranging study of MK-8591 with doravirine and lamivudine in treatment-naive adults with HIV-1

Phase 2, randomised, double-blind trial of islatravir, doravirine and lamivudine in Human immunodeficiency virus infection type 1 (3 arms), sponsored by Merck & Co. Primary endpoints: Proportion of participants with HIV-1 RNA <50 copies/mL at Week 24 and Proportion of participants with HIV-1 RNA <50 copies/mL at Week 48. Status: unknown.